Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is a biotechnology company that has a positive outlook due to their focus on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology, and their potential to generate significant revenue through their royalty-bearing assets, including Jemperli and Imsidolimab. Their partnership with GSK and Vanda provides a strong revenue stream, potentially leading to important profitability and strategies to deliver value back to shareholders. With upcoming projected approvals and a potential stock buyback, AnaptysBio has the potential for significant growth and value creation.

Bears say

AnaptysBio is a clinical-stage biotechnology company focused on developing antibody products for autoimmune and inflammatory diseases. However, the company faces multiple risks inherent in the biotech sector, including clinical, regulatory, and commercial risk, and may require significant amounts of capital to continue developing clinical programs. Additionally, ongoing litigation with GSK and uncertainty around the success of its drug pipeline could impede the stock from reaching its potential. Overall, although their CRC program shows promising data, there are significant risks and uncertainties that make AnaptysBio's stock a high-risk investment.

AnaptysBio (ANAB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 11 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.